The Demise of a Multibillion-Dollar Drug Class?

In the following video, Motley Fool health-care analyst David Williamson highlights a potential new threat to an entire class of multibillion-dollar drugs. The drug group, which treats type 2 diabetes, could be linked to pancreatitis, a very serious inflammation of the pancreas that can lead to pancreatic cancer. David tells investors how several companies, such as Merck (NYSE: MRK  ) , Bristol-Myers Squibb (NYSE: BMY  ) and AstraZeneca (NYSE: AZN  ) could be affected if the link is confirmed, and how serious the damage could be financially.

Can Merck beat the patent cliff?
This titan of the pharmaceutical industry stumbled into 2013 and continues to battle patent expirations and pipeline problems. Is Merck still a solid dividend play, or should investors be looking elsewhere? In a new premium research report on Merck, the Fool tackles all of the company's moving parts, its major market opportunities, and reasons to both buy and sell. To find out more click here to claim your copy today.



Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2319293, ~/Articles/ArticleHandler.aspx, 7/28/2014 5:46:34 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement